Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial

被引：6
|
作者：
Vart, Priya [1 ]
Jongs, Niels [1 ]
Wheeler, David C. [2 ]
Heerspink, Hiddo J. L. [1 ,3 ]
Langkilde, Anna Maria [4 ]
Chertow, Glenn M. [5 ,6 ]
机构：
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
[2] UCL, Dept Renal Med, London, England
[3] George Inst Global Hlth, Sydney, NSW, Australia
[4] AstraZeneca, BioPharmaceut R&D, Gotherburg, Sweden
[5] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA
[6] Stanford Univ, Sch Med, Dept Epidemiol & Populat Hlth, Stanford, CA 94305 USA
来源：
JAMA NETWORK OPEN | 2023年 / 6卷 / 04期
关键词：
RACIAL-DIFFERENCES; RISK;
D O I：
10.1001/jamanetworkopen.2023.10877
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Cost-Effectiveness and Clinical Outcomes of Secondary Hyperparathyroidism Treatments in Patients with Chronic Kidney Disease
    Wenjie Zhang
    Hailiang Ren
    Qianxiu Liao
    Jian Wu
    Calcified Tissue International, 2024, 114 : 368 - 376
  • [22] Safety of liraglutide vs placebo in patients with type 2 diabetes and chronic kidney disease in the LEADER trial
    Mann, J.
    Fonseca, V.
    Mosenzon, O.
    Raz, I.
    Frimer-Larsen, H.
    von Scholten, B.
    Idorn, T.
    Poulter, N.
    DIABETOLOGIA, 2018, 61 : S511 - S511
  • [23] Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial
    Heerspink, Hiddo J. L.
    Greasley, Peter J.
    Ahlstrom, Christine
    Althage, Magnus
    Dwyer, Jamie P.
    Law, Gordon
    Wijkmark, Emma
    Lin, Min
    Mercier, Anne-Kristina
    Sunnaker, Mikael
    Turton, Michelle
    Wheeler, David C.
    Ambery, Philip
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 (03) : 414 - 425
  • [24] Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease
    Martin, Edouard R.
    Smith, Mark T.
    Maroni, Bradley J.
    Zuraw, Qing C.
    deGoma, Emil M.
    AMERICAN JOURNAL OF NEPHROLOGY, 2017, 45 (05) : 380 - 388
  • [25] Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes A Prespecified Secondary Analysis of a Randomized Clinical Trial
    Zelniker, Thomas A.
    Raz, Itamar
    Mosenzon, Ofri
    Dwyer, Jamie P.
    Heerspink, Hiddo H. J. L.
    Cahn, Avivit
    Goodrich, Erica L.
    Im, Kyungah
    Bhatt, Deepak L.
    Leiter, Lawrence A.
    McGuire, Darren K.
    Wilding, John P. H.
    Gause-Nilsson, Ingrid
    Langkilde, Anna Maria
    Sabatine, Marc S.
    Wiviott, Stephen D.
    JAMA CARDIOLOGY, 2021, 6 (07) : 801 - 810
  • [26] Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease
    Ponce, Daniela
    Cardoso, Marilia Mastrocolla de Almeida
    Rugolo, Juliana Rodrigues Machado
    Molina, Silvana Andrea
    Andrade, Luis Gustavo Modelli de
    Curado, Daniel da Silva Pereira
    JORNAL BRASILEIRO DE NEFROLOGIA, 2023, 45 (03): : 365 - 372
  • [27] CERA corrects anemia in patients with chronic kidney disease not on dialysis: Results of a randomized clinical trial
    Macdougall, Iain C.
    Walker, Rowan
    Provenzano, Robert
    de Alvaro, Fernando
    Locay, Harold R.
    Nader, Paul C.
    Locatelli, Francesco
    Dougherty, Frank C.
    Beyer, Ulrich
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2008, 3 (02): : 337 - 347
  • [28] The effect of lactulose supplementation on fecal microflora of patients with chronic kidney disease; a randomized clinical trial
    Tayebi-Khosroshahi, Hamid
    Habibzadeh, Afshin
    Niknafs, Bahram
    Ghotaslou, Reza
    Sefidan, Fatemeh Yeganeh
    Ghojazadeh, Morteza
    Moghaddaszadeh, Majid
    Parkhide, Sahar
    JOURNAL OF RENAL INJURY PREVENTION, 2016, 5 (03): : 162 - 167
  • [29] Comparison of the effectiveness and safety of 2 aspirin doses in secondary prevention of cardiovascular outcomes in patients with chronic kidney disease: A subgroup analysis of ADAPTABLE
    Gupta, Kamal
    Mehta, Harsh
    Kim, Hwasoon
    Stebbins, Amanda
    Wruck, Lisa M.
    Munoz, Daniel
    Effron, Mark B.
    Anderson, R. David
    Pepine, Carl J.
    Jain, Sandeep K.
    Girotra, Saket
    DeWalt, Darren A.
    Whittle, Jeff
    Benziger, Catherine P.
    Farrehi, Peter
    Zhou, Li
    Knowlton, Kirk U.
    Polonsky, Tamar S.
    Bradley, Steven M.
    Harrington, Robert A.
    Rothman, Russell L.
    Jones, W. Schuyler
    Hernandez, Adrian F.
    AMERICAN HEART JOURNAL, 2023, 264 : 31 - 39
  • [30] Albuminuria lowering effect of dapagliflozin, eplerenone and their combination in patients with chronic kidney disease a randomised cross-over clinical trial
    Provenzano, M.
    Heerspink, H. J. L.
    Puchades, M.
    Garofalo, C.
    Jongs, N.
    Adreucci, M.
    De Nicola, L.
    Gorriz, J.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S281 - S281
12345